Volume 18, Issue 6, Pages (June 2017)

Slides:

Advertisements

Similar presentations

Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast.

Advertisements

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Volume 14, Issue 12, Pages (November 2013)

Volume 14, Issue 4, Pages (April 2013)

Volume 16, Issue 8, Pages (August 2015)

Volume 385, Issue 9980, Pages (May 2015)

Ki67 in breast cancer: prognostic and predictive potential

Volume 12, Issue 9, Pages (September 2011)

Volume 16, Issue 2, Pages (February 2015)

Volume 6, Issue 7, Pages (July 2005)

Volume 390, Issue 10099, Pages (September 2017)

Volume 18, Issue 7, Pages (July 2017)

Volume 16, Issue 9, Pages (September 2015)

Volume 15, Issue 6, Pages (May 2014)

Volume 14, Issue 10, Pages (September 2013)

Volume 19, Issue 2, Pages (February 2018)

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9783, Pages (June 2011)

Volume 9, Issue 12, Pages (December 2008)

Volume 9, Issue 5, Pages (May 2008)

Volume 15, Issue 8, Pages (July 2014)

Volume 15, Issue 2, Pages (February 2014)

Volume 374, Issue 9707, Pages (December 2009)

Volume 15, Issue 4, Pages (April 2014)

Volume 373, Issue 9663, Pages (February 2009)

Volume 12, Issue 12, Pages (November 2011)

Volume 366, Issue 9484, Pages (August 2005)

Volume 18, Issue 7, Pages (July 2017)

Volume 12, Issue 7, Pages (July 2011)

Volume 8, Issue 4, Pages (April 2009)

Volume 15, Issue 6, Pages (May 2014)

Volume 16, Issue 6, Pages (June 2015)

Volume 18, Issue 3, Pages (March 2017)

Volume 379, Issue 9812, Pages (January 2012)

Volume 15, Issue 1, Pages (January 2014)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild- type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised.

Volume 16, Issue 1, Pages (January 2017)

Volume 390, Issue 10099, Pages (September 2017)

Volume 6, Issue 6, Pages (June 2005)

Volume 14, Issue 6, Pages (May 2013)

Volume 11, Issue 4, Pages (April 2010)

Volume 20, Issue 1, Pages (January 2019)

Volume 14, Issue 11, Pages (October 2013)

Volume 373, Issue 9666, Pages (March 2009)

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,

Volume 19, Issue 4, Pages (April 2018)

Volume 15, Issue 8, Pages (July 2014)

Volume 373, Issue 9676, Pages (May 2009)

Volume 18, Issue 8, Pages (August 2017)

Volume 16, Issue 15, Pages (November 2015)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Volume 15, Issue 6, Pages (May 2014)

Volume 381, Issue 9880, Pages (May 2013)

Volume 14, Issue 6, Pages (May 2013)

Volume 13, Issue 11, Pages (November 2012)

Volume 11, Issue 3, Pages (March 2010)

Volume 16, Issue 15, Pages (November 2015)

Low-technology approaches

Volume 19, Issue 2, Pages (February 2018)

Volume 375, Issue 9714, Pages (February 2010)

Volume 15, Issue 6, Pages (May 2014)

Volume 15, Issue 1, Pages (January 2014)

Volume 15, Issue 8, Pages (July 2014)

Volume 11, Issue 1, Pages (January 2010)

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

DHA-Paclitaxel (Taxoprexin) as First-Line Treatment in Patients with Stage IIIB or IV Non-small Cell Lung Cancer: Report of a Phase II Open-Label Multicenter.

Volume 13, Issue 5, Pages (May 2012)

Volume 5, Issue 1, Pages (January 2018)

Volume 14, Issue 7, Pages (June 2013)

Clinic attendance and disengagement of young adults with type 1 diabetes after transition of care from paediatric to adult services (TrACeD): a randomised,

Presentation transcript:

Volume 18, Issue 6, Pages 755-769 (June 2017) Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial Professor Helena M Earl, MBBS, Louise Hiller, PhD, Helen C Howard, PhD, Prof Janet A Dunn, PhD, Jennie Young, BA, Sarah J Bowden, PhD, Michelle McDermaid, Anna K Waterhouse, BSc, Gregory Wilson, FRCP, Rajiv Agrawal, FRCR, Susan O'Reilly, MD, Angela Bowman, MB ChB, Diana M Ritchie, MD, Andrew Goodman, MB ChB, Prof Tamas Hickish, MD, Karen McAdam, FRCP, Prof David Cameron, MD, Prof David Dodwell, MD, Daniel W Rea, FRCP, Prof Carlos Caldas, MD, Elena Provenzano, PhD, Jean E Abraham, PhD, Peter Canney, MD, Prof John P Crown, FRCPI, Prof M John Kennedy, FRCPI, Prof Robert Coleman, FRCP, Prof Robert C Leonard, MD, James A Carmichael, MD, Prof Andrew M Wardley, MD, Prof Christopher J Poole, FRCP The Lancet Oncology Volume 18, Issue 6, Pages 755-769 (June 2017) DOI: 10.1016/S1470-2045(17)30319-4 Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet Oncology 2017 18, 755-769DOI: (10.1016/S1470-2045(17)30319-4) Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 2 Disease-free survival and overall survival (A) Disease-free survival. (B) Overall survival. HR=hazard ratio. *Adjusted for stratification variables. The Lancet Oncology 2017 18, 755-769DOI: (10.1016/S1470-2045(17)30319-4) Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 3 Disease-free survival, by prognostic factors (age, hormone receptor status, nodal status, and HER-2 status) Size of box reflects size of sample within each stratum. The Lancet Oncology 2017 18, 755-769DOI: (10.1016/S1470-2045(17)30319-4) Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 4 Disease-free survival, by prognostic factors (performance status, surgery, tumour size, grade, and lymphovascular space invasion) Size of box reflects size of sample within each stratum. ECOG=Eastern Cooperative Oncology Group. The Lancet Oncology 2017 18, 755-769DOI: (10.1016/S1470-2045(17)30319-4) Copyright © 2017 Elsevier Ltd Terms and Conditions

Figure 5 Disease-free survival, by prognostic factors (triple negative status and combined grade, hormone receptor, and HER-2 status) Size of box reflects size of sample within each stratum. The Lancet Oncology 2017 18, 755-769DOI: (10.1016/S1470-2045(17)30319-4) Copyright © 2017 Elsevier Ltd Terms and Conditions